Menno V. Huisman, M.D., Ph.D., from the Leiden University Medical Center in the Netherlands, and colleagues compared phase 2 baseline data with the pre-NOAC era data collected during phase 1.

Frail patients with atrial fibrillation who were switched to a newer NOAC agent had more bleeding than those left on older vitamin K antagonists, without any benefit in terms of thromboembolic events.

In patients with atrial fibrillation undergoing PCI, antithrombotic regimens involving a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) should be avoided, whereas use of a non-VKA ...

Uninterrupted treatment with novel oral anticoagulants during catheter ablation of atrial fibrillation is safe, reveals research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Dr Carsten ...